I'm pretty sure avodart is used for benign prostatic hypertrophy - I dont think your list is very accurate. Avastin is not 1st line treatment for ovarian patients and would generally only be available if self funded. Ovarian cancer patients would receive an anthracycline and taxane as first line, then there are options including caelyx, topotecan, gemcytabine, etc....Reality is that PRR would probably only get approval (especially in Aus) as 3rd or 4th line treatment which would significantly reduce the patient pool. There are significantly more prostate cancer patients than ovarian and they are diagnosed much earlier so the need for more lines of treatment is greater. Unfortunately most ovarian cancer patients are diagnosed so late that they don't get through many lines of chemo treatment.
- Forums
- ASX - By Stock
- IMM
- dndn is not prr
dndn is not prr, page-13
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
40.0¢ |
Change
0.005(1.27%) |
Mkt cap ! $581.0M |
Open | High | Low | Value | Volume |
38.5¢ | 41.0¢ | 38.5¢ | $1.351M | 3.389M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 16911 | 40.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
40.5¢ | 154170 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 16911 | 0.400 |
6 | 104590 | 0.395 |
6 | 65668 | 0.390 |
6 | 98699 | 0.385 |
10 | 114110 | 0.380 |
Price($) | Vol. | No. |
---|---|---|
0.405 | 154170 | 1 |
0.410 | 259670 | 7 |
0.415 | 187366 | 8 |
0.420 | 484307 | 7 |
0.425 | 69000 | 3 |
Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |